PDCD1 and neoplasm: Nivolumab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), thereby restoring anti-tumor immunity by blocking PD-1/programmed death-ligand 1 (PD-L1) interactions and reactivating T-cell responses.